These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17114666)

  • 1. Thalidomide use and digital gangrene.
    Kang TY; Lowe CJ; Sekeres MA
    J Clin Oncol; 2006 Nov; 24(33):5328. PubMed ID: 17114666
    [No Abstract]   [Full Text] [Related]  

  • 2. Thalidomide therapy in compensated and decompensated myelofibrosis with myeloid metaplasia.
    Pozzato G; Zorat F; Nascimben F; Comar C; Kikic F; Festini G
    Haematologica; 2001 Jul; 86(7):772-3. PubMed ID: 11454539
    [No Abstract]   [Full Text] [Related]  

  • 3. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
    Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
    Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and tolerance of low to very low dose thalidomide in low-risk myelodysplastic syndromes.
    Tamburini J; Elie C; Park S; Beyne-Rauzy O; Gardembas M; Berthou C; Mahe B; Sanhes L; Stamatoullas A; Vey N; Aouba A; Slama B; Quesnel B; Vekhoff A; Sotto JJ; Vassilief D; Al-Nawakil C; Fenaux P; Dreyfus F; Bouscary D;
    Leuk Res; 2009 Apr; 33(4):547-50. PubMed ID: 18640718
    [No Abstract]   [Full Text] [Related]  

  • 5. [Advances in thalidomide therapy for idiopathic myelofibrosis].
    Song L; Chen JL
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Oct; 31(5):651-3. PubMed ID: 19968089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Encephalopathy in a patient after long-term treatment with thalidomide.
    Sohlbach K; Heinze S; Shiratori K; Sure U; Pagenstecher A; Neubauer A
    J Clin Oncol; 2006 Oct; 24(30):4942-4. PubMed ID: 17050881
    [No Abstract]   [Full Text] [Related]  

  • 7. Thalidomide for the treatment of chronic gastrointestinal bleeding from angiodysplasias: a case series.
    Kamalaporn P; Saravanan R; Cirocco M; May G; Kortan P; Kandel G; Marcon N
    Eur J Gastroenterol Hepatol; 2009 Dec; 21(12):1347-50. PubMed ID: 19730385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thalidomide in POEMS syndrome: case report.
    Sinisalo M; Hietaharju A; Sauranen J; Wirta O
    Am J Hematol; 2004 May; 76(1):66-8. PubMed ID: 15114600
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective study of combination therapy with low-dose thalidomide plus prednisolone ameliorating cytopenia in primary myelofibrosis.
    Hattori Y; Miyakawa Y; Yokoyama K; Yamada T; Du W; Jinzaki M; Shinmoto H; Okamoto S
    Int J Hematol; 2011 Jan; 93(1):129-31. PubMed ID: 21153775
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and tolerability of low-dose thalidomide as first-line systemic treatment of patients with advanced hepatocellular carcinoma.
    Yau T; Chan P; Wong H; Ng KK; Chok SH; Cheung TT; Lam V; Epstein RJ; Fan ST; Poon RT
    Oncology; 2007; 72 Suppl 1():67-71. PubMed ID: 18087184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment considerations for primary myelofibrosis.
    Biemond BJ
    Neth J Med; 2010 Aug; 68(1):291-2. PubMed ID: 20739724
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-dose thalidomide in myelofibrosis.
    Weinkove R; Reilly JT; McMullin MF; Curtin NJ; Radia D; Harrison CN
    Haematologica; 2008 Jul; 93(7):1100-1. PubMed ID: 18508796
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.
    Plasmati R; Pastorelli F; Cavo M; Petracci E; Zamagni E; Tosi P; Cangini D; Tacchetti P; Salvi F; Bartolomei I; Michelucci R; Tassinari CA
    Neurology; 2007 Aug; 69(6):573-81. PubMed ID: 17679676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide in agnogenic and secondary myelofibrosis.
    Canepa L; Ballerini F; Varaldo R; Quintino S; Reni L; Clavio M; Miglino M; Pierri I; Gobbi M
    Br J Haematol; 2001 Nov; 115(2):313-5. PubMed ID: 11703326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial.
    Musallam KM; Taher AT
    J Natl Cancer Inst; 2009 Dec; 101(23):1657; author reply 1657-8. PubMed ID: 19858426
    [No Abstract]   [Full Text] [Related]  

  • 16. Thalidomide and bowel perforation: four cases in one hospital.
    McClay H; Cervi P
    Br J Haematol; 2008 Feb; 140(3):360-1. PubMed ID: 18042266
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of second primary malignancy in patients with AL amyloidosis treated with lenalidomide.
    Sanchorawala V; Shelton AC; Zeldis JB; Seldin DC
    Am J Hematol; 2013 Aug; 88(8):719. PubMed ID: 23650113
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
    Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
    Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of thalidomide in the treatment of myelodysplastic syndromes.
    Piccaluga PP; Visani G; Finelli C; Grafone T; Baccarani M; Tura S
    Haematologica; 2002 Mar; 87(3):ELT18. PubMed ID: 11869964
    [No Abstract]   [Full Text] [Related]  

  • 20. Hypercoagulable states in patients with multiple myeloma can affect the thalidomide-associated venous thromboembolism.
    Talamo GP; Ibrahim S; Claxton D; Tricot GJ; Fink LM; Zangari M
    Blood Coagul Fibrinolysis; 2009 Jul; 20(5):337-9. PubMed ID: 19367157
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.